垂体促甲状腺素腺瘤的研究进展

Research progress of thyrotropinomas adenoma

垂体促甲状腺素腺瘤(thyrotropinomas,TSH瘤)是来源于垂体促甲状腺细胞的肿瘤。此种垂体瘤发病率较低,自首例TSH瘤报道至今全球报道的病例数约450多例。TSH瘤的临床表现为甲状腺功能亢进症。实验室检查可见甲状腺激素水平增高,促甲状腺激素水平不被抑制。垂体核磁(Magnetic resonance imaging,MRI)提示鞍区占位。目前首选治疗方法为经碟手术切除肿瘤,此外还有放射治疗、药物治疗。但TSH瘤多为侵袭性肿瘤,单一手术难以彻底治愈,所以多采用手术结合药物进行治疗,与单一药物治疗TSH瘤的方法被国内外医生广泛重视。目前国内外有关于手术结合药物治疗的报道不占少数,但关于单一运用药物治疗TSH瘤的报道甚少。

Pituitary thyrotropinoma（TSH） adenoma is a tumor derived from pituitary thyrotropin-secreting cells. The in cidence of this pituitary tumor is low, and since the first case of TSH adenoma, there have been reported over 450 cases around the world. The clinical manifestation is hyperthyroidism. Laboratory tests show increased thyroid hormone levels,and non-inhibition of thyrotropin levels. Pituitary magnetic resonance imaging（MRI） suggests a sellar region lesion.At present the preferred treatment is transsphenoidal surgical resection. In addition, there are radiation therapy and drug therapy. However, TSH tumors are mostly invasive tumors, and a single operation is difficult to completely cure it.Therefore, surgery combined with drug therapy, with a single drug treatment of TSH tumor is prioritized by domestic and foreign doctors. At present, there are a substantial number of reports about the combination of surgery and drug therapy, but there is little report about the treatment of TSH with single drug.